LACK OF APPARENT HEMATOLOGIC ABNORMALITIES IN HUMAN PATIENTS WITH c-kit (STEM CELL FACTOR RECEPTOR) GENE MUTATIONS
To the Editor:
Considerable attention has recently been paid to the molecular biology, cell biology, and mutations of the mouse Steel (SI) and dominant white spotting (W; c-kit) loci, which respectively encode stem cell (SCF; also referred to as mast cell growth and kit ligand7-9) and its cognate cellular receptor tyrosine kinase.'O Mice with mutations at either of these loci have similar developmental defects of the melanocyte, pre-erythroid, and germ cell lineages. In addition to characteristic pigmentary anomalies (white spotting), affected mice exhibit a hypoplastic macrocytic anemia. Ten of 24 murine W mutant c-kit alleles result in anemia even in the heterozygote, and virtually all W alleles result in profound (often lethal) anemia in the homozygote.11-12
Recently, we have shown that human c-kit gene mutations result in piebaldi~m,'~J~ a well-known autosomal dominant genetic disorder characterized only by white spotting. Human piebaldism was one of the first genetic disorders ever recognized, and has never been associated with anemia. Specifically, hematologic abnormalities were not described in any of 42 unrelated probands with heterozygous piebaldism reported since 1950. Table 1 shows hematologic data of six additional patients with heterozygous piebaldism in whom we have defined specific c-kit gene mutations; all values were within the normal ranges for the respective laboratories. In addition, the hematologic values of a previously reported patient with apparent homozygous autosomal dominant piebaldi~m'~ were also entirely normal (M. Hulten, personal communication, September 1991), although his c-kit genes have not yet been analyzed.
The c-kit gene is expressed in human erythroleukemia cell lines,I6 and recombinant human SCF enhances the in vitro proliferative response of cultured human marrow cells to other growth factors, including interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor, and erythropoietin (EPo).'~ Moreover, c-kit antisense oligonucleotides inhibit both (IL-3 + Epo)-and (SCF + Epo)-stimulated human erythroid colony proliferation in vitro.'* All of these data are consistent with a role for c-kit in human erythropoiesis. How, then, might the lack of apparent hematologic abnormalities in patients with piebaldism be explained?
One trivial possibility is that many mutant human c-kit alleles do result in significant anemia in the heterozygote, but these alleles have just not yet been observed. The two human c-kit frameshifts that we have described14 result in "null" alleles, and thus are For personal use only. on October 30, 2017. by guest www.bloodjournal.org From analogous to the classic murine W allele, which produces no hematologic phenotype in the heterozygote.11s'2 However, c-kit mutations apparently account for a very significant fraction of human piebaldism (we have found pathologic c-kt mutations in each of the six unrelated probands we have studied) but, as noted above, anemia has never been described in any of the very large number of piebald patients reported to date. Furthermore, the one known patient with homozygous piebaldism exhibited no hematologic abnormalities.
Another possibility may be that most or all mutant c-kit alleles result in hematologic phenotypes too subtle to be readily detected on the outbred genetic background of humans. This would be of considerable interest, as it would suggest that the c-kt-encoded SCF receptor is not required for normal development and maintenance of the human erythroid cell lineage in vivo. It may be, for example, that in humans the SCF receptor is functionally redundant in the erythroid lineage.
Alternatively, in humans, in contrast to in mice, most c-kit gene mutations may result in a relatively severe phenotype that is incompatible with life, even in the heterozygote, either because of severe anemia or because of other pleiotropic effects. In this instance only alleles that have mild effects on erythropoiesis might be observed. This seems relatively unlikely, as at least some alleles resulting in intermediate effects might be expected.
Finally, it might also be that in humans some c-kit mutations result essentially only in pigmentary abnormalities whereas others result essentially only in hematologic abnormalities, and that these effects are mutually exclusive. This seems highly improbable, and runs counter to the aggregate experience with mice carrying different Walleles, in which c-kit mutations typically exert pleiotropic phenotypic effects.
Whatever the correct explanation, it appears that humans with piebaldism resulting from c-kit gene mutations do not typically exhibit the erythropoietic abnormalities often apparent in W mutant laboratory mice. This difference underscores the need for caution when predicting the developmental consequences of human genetic disorders based on the analogous animal models. 
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It is interesting that c-kit mutations in humans cause piebaldism but no detectable anemia. As Dr Spritz mentions, the humans characterized thus far are heterozygous for null mutations and, like the mice with a single copy of the null c-kit, have normal blood values. Thus, one would not expect the patients to be severely affected. A cautionary note is that the mice heterozygous for the null mutant gene are not really normal. Evidence of abnormal blood formation is the finding that hematopoietic cells from heterozygotes do not compete well with cells from normal mice during repopulation.' Thus, piebald patients with no apparent deleterious effects on hematopoiesis, when stressed by, for example, suppressive anticancer drug treatment, might show severe abnormalities.
Mice with mutations in c-kit that cause production of a functional but aberrant protein are usually anemic as heterozygotes. One might expect to find such mutations in the human population. As Dr Spritz points out, it is surprising that among the many piebald patients studied to date there is no anemia. However, there is a major difference between the mice and the humans in that the mice are highly inbred. Therefore, all the mice are essentially the same genetically, except at the W locus, whereas the humans are heterogeneous. How do you evaluate the red blood cell (RBC) counts between patients and normal sibs when you are looking for a subtle difference? Even in the mice, it is sometimes difficult to confirm the anemia in the heterozygote. For example, mice with the mutation W41J as heterozygotes have an RBC count of 9.21 2 0.07 (SEM) x 109/mL while the +/+ littermates have an RBC count of 9.84 2 0.04 x 109/mL.Z Even in the affected homozygote, the RBC count is 8.19 * 0.09, so there really is not much variation between normal and mutants. In fact, it required blood tests on large numbers of mice to prove the difference is statistically significant.
The information that there is at least one nonanemic homozygous piebald patient from consanguinous parents is not surprising. There is at least one mouse mutant, Ww/w4, that is also not anemic. Again, this mouse has a hematopoietic defect because it does accept marrow from a normal littermate without prior irradiation3 and its own marrow cells produce characteristically few macroscopic spleen colonies in an irradiated +/ + host?
Another tissue where there appears to be differences between human and mouse c-kit mutants is the brain. The mice have no obvious clinical symptoms of neural insufficiency, despite the fact that the brain generates more c-kit mRNA than other tissue? There are, on the other hand, descriptions of piebald patients who exhibit neurologic problem^.^,^ Given the previous arguments, it is entirely possible that the mice exhibit subtle differences in brain physiology that we have not yet discovered (while the piebald patients actually have aberrant hematopoiesis). If this is the case, then the piebald patients may, in fact, be excellent models of the murine disease! JANE E. BARKER The Jackron Laboratory Bar Harbor ME
